Introduction and Objective: According to the CDC 40.3% of adults in the US have obesity. Persons with DM1 are not exempt from this and its metabolic comorbidities. We evaluated retrospectively the glycemic outcomes and weight effect of GLP1analogs added and titrated during routine office visits to 45 patients with DM1 current users of minimed 780G AID (avg 287 SD 166 days before GLP1) (Tirzepatide 26, Semaglutide18, Dulaglutide1) Methods: EMR from a DM clinic in San Antonio TX were evaluated. Data of patient’s AID at 3-month intervals for 1 year was analyzed and compared with a cohort of randomly chosen control group of 45 patients also users of same AID system not using of GLP1 analogs (One way ANOVA RM) Results: In the AID-GLP1 analog group, BMI and total insulin significantly decreased over time (*P0.00005). Favorable changes in HgbA1c, GMI and time in range were modest but significant (**P0.005); No changes on time below range were observedThe AID control group showed no significant changes in BMI, total insulin used, A1c, GMI, time in or below rangeHighest dose of GLP1 analog used in % was 50 SD 30 Conclusion: In persons with DM1 and obesity, AID users, the addition of GLP1 analogs significantly decreased BMI and total insulin used, improving metabolic parameters associated with insulin resistance. Modest but significant improvements in overall glycemic parameters over AID alone were also noted Disclosure W. Trigoso: Speaker's Bureau; Current; Lilly, Boehringer Ingelheim International GmbH. T.M. Copple: Speaker's Bureau; Current; Kyowa Kirin Co., Ltd. A.J. Greenfield: None.
Trigoso et al. (Fri,) studied this question.